• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

LC–MS/MS Determination of Prednisone, A Drug in Phase 4 of Multiple Sclerosis Therapy along with Teriflunomide and Pioglitazone in Rat Plasma
  • VIEWS 1827
  • PDF 903

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v20i4.MS21076

Year: 2021, Volume: 20, Issue: 4, Pages: 50-57

Original Article

LC–MS/MS Determination of Prednisone, A Drug in Phase 4 of Multiple Sclerosis Therapy along with Teriflunomide and Pioglitazone in Rat Plasma

Raja K Rajeswari​ ✉ 1, A Suneetha 2

1 Associate Professor, Department of Pharmaceutical Analysis, Sri Venkateswara College of Pharmacy, Etcherla, Srikakulam­, Andhra Pradesh, 532 410, India
2 Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur­, Andhra Pradesh, 522 002, India
✉ Corresponding author: [email protected]
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Combination therapy or polytherapy is that uses more than one medication to treat a single disease and associated diseases. Pharmaceutical combination therapy may be achieved by prescribing separate drugs, or, where available, dosage forms that contain more than one active ingredient. A randomized efficacy phase 4 study is going on for prednisone in the treatment of multiple sclerosis, which is a neurodegenerative disease associated with many other disorders. A novel and accurate liquid chromatography tandem mass spectrometry method using electrospray ionization mode has been developed and validated for the simultaneous determination of prednisone (PDN), pioglitazone (PGZ) and teriflunomide (TFM) using imipramine (IMP) and ibuprofen (IBP) as internal standards (IS). The separation was carried on XTerra MS C18 (100 mm x 3.9 mm, 5 µm) reversed phase column using acetonitrile and 0.01M ammonium formate as the mobile phase in gradient mode at 1.0 mL/min. The method was validated in terms of specificity, linearity, accuracy and precision over the concentration range of 1–500 ng/mL. The intra and inter-day precision and accuracy, stability and extraction recoveries of all the analytes were found in the range of 97.2-102.2%. The lower limit of quantitation was 1.0 ng/mL for all the 3 analytes and the extraction recovery values were more than 65%. The method proved highly reproducible and sensitive and was successfully applied to pharmacokinetic study after single dose oral administration of PDN, PGZ and TFM to the rats.

 

Keywords

Polytherapy, Teriflunomide, Prednisone, Pioglitazone, Phase 4, Multiple Sclerosis, Pharmacokinetics

References

  1. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs. 2014;74(6):659–674. Available from: https://dx.doi.org/10.1007/s40265-014-0212-x
  2. Schmidt A, Schwind B, Gillich M, Brune K, Hinz B. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomedical Chromatography. 2003;17(4):276–281. Available from: https://dx.doi.org/10.1002/bmc.244
  3. Roon ENv, Yska JP, Raemaekers J, Jansen TLTA, Wanrooy Mv, Brouwers JRBJ. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. Journal of Pharmaceutical and Biomedical Analysis. 2004;36(1):17–22. Available from: https://dx.doi.org/10.1016/j.jpba.2004.05.019
  4. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clinical Therapeutics. 2001;23(11):1792–1823. Available from: https://dx.doi.org/10.1016/s0149-2918(00)80078-8
  5. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM, . Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85–109. doi: 10.2165/00003495-200666010-00005
  6. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) Journal of Biological Chemistry. 1995;270(22):12953–12956. Available from: https://dx.doi.org/10.1074/jbc.270.22.12953
  7. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The Structure−Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones. Journal of Medicinal Chemistry. 1996;39(3):665–668. Available from: https://dx.doi.org/10.1021/jm950395a
  8. Eckland D, Danhof M. Clinical pharmacokinetics of pioglitazone. Experimental and Clinical Endocrinology & Diabetes. 2000;108(Sup. 2):234–242. Available from: https://dx.doi.org/10.1055/s-2000-8525
  10. Yamashita K, Murakami H, Teruaki O, Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. Journal of Chromatography B: Biomedical Sciences and Applications. 1996;677(1):141–146. Available from: https://dx.doi.org/10.1016/0378-4347(95)00440-8
  13. Lin ZJ, Ji W, Desai-Krieger D, Shum L. Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2003;33(1):101–108. Available from: https://dx.doi.org/10.1016/s0731-7085(03)00344-3
  14. Wong HH, Ozalp Y, Lainesse A, Alpan RS. In vivo Bioequivalence of Oral Antidiabetic Agents: Pioglitazone Tablets. Arzneimittelforschung. 2004;54(09):618–624.
  15. Rakhila H, Rozek T, Hopkins A, Proudman S, Cleland L, James M, et al. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2011;55(2):325–331. Available from: https://dx.doi.org/10.1016/j.jpba.2011.01.034
  17. Sobhani K, Garrett DA, Liu DP, Rainey PM. A Rapid and Simple High-Performance Liquid Chromatography Assay for the Leflunomide Metabolite, Teriflunomide (A77 1726), in Renal Transplant Recipients. American Journal of Clinical Pathology. 2010;133(3):454–457. Available from: https://dx.doi.org/10.1309/ajcpr23yaoyfsztx
  19. Sengupta P, Bhaumik U, Ghosh A, Sarkar AK, Chatterjee B, Bose A, et al. LC–MS–MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study. Chromatographia. 2009;69(11-12):1243–1250. Available from: https://dx.doi.org/10.1365/s10337-009-1056-5
  20. Gananadhamu S, Laxmikanth V, Shantikumar S, Sridhar V, Geetha C, Sandhya C. Rapid LC-ESI-MS-MS Method for the Simultaneous Determination of Sitagliptin and Pioglitazone in Rat Plasma and Its Application to Pharmacokinetic Study. American Journal of Analytical Chemistry. 2012;03(12):849–858. Available from: https://dx.doi.org/10.4236/ajac.2012.312112
  22. Beotra A, Jain S, Ahi S, Reddy I. A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples. Indian Journal of Pharmacology. 2009;41(2):80. Available from: https://dx.doi.org/10.4103/0253-7613.51347
  23. Fu-Yan L, Jun J, Yuan-chao X, Yong-hua D. LC-MS determination of diclofenac and prednisone acetate illegally mixed into traditional Chinese medicine preparations. Chinese Journal of Pharmaceutical Analysis. 2009;29:2131–2133.

Copyright

© 2021 Published by Krupanidhi Educational Trust. This is an open-access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)

  • 18 February 2022

Year: 2021, Volume: 20, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.